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Abstract
Background: There are over 700 known arboviruses and at least 80 immunologically distinct types that cause
disease in humans. Arboviruses are transmitted among vertebrates by biting insects, chiefly mosquitoes and ticks.
These viruses are widely distributed throughout the world, depending on the presence of appropriate hosts (birds,
horses, domestic animals, humans) and vectors. Mosquito-borne arboviruses present some of the most important
examples of emerging and resurgent diseases of global significance.
Methods: A strategy has been developed by which host-range mutants of Dengue virus can be constructed by
generating deletions in the transmembrane domain (TMD) of the E glycoprotein. The host-range mutants
produced and selected favored growth in the insect hosts. Mouse trials were conducted to determine if these
mutants could initiate an immune response in an in vivo system.
Results: The DV2 E protein TMD defined as amino acids 452SWTMKILIGVIITWIG467 was found to contain specific
residues which were required for the production of this host-range phenotype. Deletion mutants were found to be
stable in vitro for 4 sequential passages in both host cell lines. The host-range mutants elicited neutralizing
antibody above that seen for wild-type virus in mice and warrant further testing in primates as potential vaccine
candidates.
Conclusions: Novel host-range mutants of DV2 were created that have preferential growth in insect cells and
impaired infectivity in mammalian cells. This method for creating live, attenuated viral mutants that generate safe
and effective immunity may be applied to many other insect-borne viral diseases for which no current effective
therapies exist.
Background
Dengue Virus (DV), the most prevalent arbovirus, is in
the family Flaviviridae and has four distinct serotypes
which cause an acute disease of sudden onset with
headache, fever, prostration, myalgia, lymphadenopathy
and rash [1,2]. DV is transmitted by mosquitoes and as
distribution and density of these insects has expanded, a
considerable increase in Dengue transmission has been
observed in tropical and subtropical areas throughout
the world, with about 50 million cases of Dengue Fever
and 500,000 cases of the more severe Dengue Haemor-
rhagic Fever (DHF). Over 20,000 deaths each year can
be attributed to DHF, ranking Dengue with tuberculosis,
STDs (including HIV), childhood diseases or malaria in
costs of care and economic impact. DV is also the only
known arbovirus that has fully adapted to the human
host and has lost the need of an enzootic cycle for
maintenance [1]. The lack of prophylactics, vaccines or
antivirals against DV alone leaves 2 billion people at risk
yearly to contract this disease [1].
DV is an enveloped virus with an icosahedral capsid
that contains a single-stranded, positive sense RNA gen-
ome [3]. The envelope of DV is composed of hetero-
dimers of the (E) glycoprotein and the membrane (M)
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any medium, provided the original work is properly cited.protein that are embedded in a host-derived lipid bilayer
(Figure 1). The nucleocapsid is composed entirely of
capsid (C) protein and encapsulates the RNA genome.
The E glycoprotein is important for cell receptor attach-
ment and subsequent infection of the target cell mem-
brane, and bears the neutralization epitopes [4]. DV, as
well as all arboviruses, has evolved to replicate in the
unique biochemical environments of both vertebrate
and invertebrate hosts [5]. As a result, the mature
viruses are hybrid structures which derive their lipid
bilayers from the host cell. Hence, composition of the
outer surface of mature dengue virions varies depending
u p o nt h et y p eo fh o s tc e l li nw h i c ht h ev i r u sw a sp r o -
duced. Insect cell membranes do not contain endogen-
ous cholesterol and are composed of shorter-chain
lipids than mammalian membranes [6]. Consequently,
insect cell membranes are thinner in cross-section as
compared to mammalian membranes [7-10]. The mem-
brane-spanning domains (transmembrane domains;
TMD) of proteins integrated into insect cell membranes
have evolved to accommodate both host membranes.
However, it is hypothesized that shorter transmembrane
domains of viruses can be tolerated in insect cell mem-
branes verses mammalian membranes [11]. In Sindbis
virus (SV), an arbovirus of the family Alphaviridae, large
truncations of the E2 TMD are tolerated in insect hosts,
but not mammalian cells, confirming the theory that
insect cells do not require the same membrane spanning
length of E2 as those integrated into mammalian mem-
branes [11]. This host-derived TMD difference was used
to develop a method for production of viral mutants
with truncated TMDs that are capable of efficient
growth in invertebrate cells but with impaired replica-
tion in vertebrate cells [11]. A targeted and rational
method of deleting amino acids in the TMD of the
envelope glycoproteins was used to create DV serotype
2 (DV2) mutants with preferential growth in the insect
host (Patent No. 6,589,533). Based on the SV model, it
was predicted that deleting amino acids in the TMD of
t h eEo rMp r o t e i n so fd e n g u ev i r u sw o u l dm a k et h e s e
domains shorter such that they would be capable of
spanning an insect but not the mammalian cell mem-
brane. This alteration was expected to result in the pro-
duction of mutant virus which demonstrated reduced
infectivity in mammalian hosts but retained efficient
growth in insect hosts, producing a host-range pheno-
type. Deletions in the TMD of SV resulted in virus with
altered infectivity and host-range [11]. Both E and M
proteins of DV have a TMD that can be targeted for
deletion mutation analysis using the SV TMD deletion
strategy. In the study reported herein, mutants of DV2
were created and analysed for a host-range phenotype
with preferential growth in insect cells. Mosquito-prefer-
ential DV2 host-range mutants were created by this
deletion strategy; however, it was determined that other
factors irrespective of TMD length also affect pheno-
type. Truncations of 3 to 4 amino acids in the TMD of
the DV2 E domain at positions between amino acids
458 to 463 resulted in virus with attenuated growth in
mammalian cells that maintained the ability to replicate
in mosquito cells while larger deletions resulted in
either no or very low levels of virus production and
infectivity. When injected into mice, these mutants were
found to elicit a higher level of neutralizing antibody
than the wild-type virus and warrant further study as
potential vaccine candidates.
Methods
Cell Culture
C6/36 cells (Aedes albopictus, American Type Culture
Collection [ATCC] # CRL-1660, Manassas, VA) were
maintained in minimal essential medium (MEM) con-
taining Earl’s salts supplemented with 10% fetal bovine
serum (FBS), 5% tryptose phosphate broth (TPB) and 2
mM L-glutamine. Vero cells (African Green monkey
kidney, ATCC #CCL-81) were maintained in 1X MEM
supplemented with 10% FBS, 5% TPB, 2 mM L-gluta-
mine, 10 mM Hepes pH 7.4 and 1X MEM nonessential
amino acids (NEAA) (1:100 dilution of NEAA from
Gibco #11140, Carlsbad, CA).
Construction of DV2 deletion mutants
A full-length cDNA clone of Dengue serotype 2 (DV2;
Thai strain 16681, GenBank # U87411) in pGEM3z+
was obtained from the Walter Reed Army Institute of
Research for these studies [12]. The clone produces full-
Figure 1 Schematic representation of the organization of
dengue virus polyprotein. Representation of DV protein structure
illustrating the predicted orientation across the endoplasmic
reticulum (ER). Cylinders represent transmembrane (T) helices. prM,
membrane protein precursor; E, envelope protein; NS1, non-
structural protein. The sequences of the E protein T1 and M protein
T1 are shown. Underlined residues indicate the amino acids
targeted for deletion. The TM domain of the capsid protein is
cleaved during processing and is not present in the membrane of
the assembled virus.
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RNA polymerase and after transfection of the transcripts
into mammalian or insect cells, infectious virions were
generated.
Deletions in the TMD of the DV2 E and M proteins
were produced by polymerase chain reaction (PCR)-
based site-directed mutagenesis, using Pfu Turbo
® DNA
polymerase AD (Stratagene, La Jolla, CA). Primers were
designed to create sets of single, double, triple, quadru-
ple, and quintuple amino acid (aa) deletions within the
T1 domain of the E or M protein of DEN2. PCR condi-
t i o n sw e r ea sf o l l o w s :2 5n gD V 2D N A ,1 Xo r1 . 5 XPfu
Turbo Buffer, 0.4 mM/μL dNTPs (New England Biolabs,
Ipswich, MA), 5 ng/μL each primer, and 0.1 U/μL Pfu
Turbo DNA polymerase AD. Reactions were run with
and without DMSO (4% final concentration). PCR cycles
were as follows: 95°C for 2 min, then 25 cycles of 95°C
for 15 sec, 45 sec of annealing (TA = Primer Tm-5°C for
each set of primers), 68°C for 24 min. Extension was
performed for 28 min at 68°C; samples were held at 4°C
until analysis by gel electrophoresis. Following mutagen-
esis of the WT DV2 clone, the PCR products were
digested with DpnI (New England Biolabs) and trans-
formed into SURE
®2 Supercompetent E.coli cells (Stra-
tagene) as per manufacturer’s instructions with a few
alterations. Following heat shock and recovery on ice,
room temperature NZY
+ broth (Teknova, Hollister, CA)
was added and incubation was performed at 30°C for 1
to 2 hours with shaking. After plating on Luria Broth
(LB) agar containing 50 μg/mL carbenicillin (Teknova)
incubation was performed at 30°C for 32 to 48 hours. A
colony PCR screen [13] was then used to quickly iden-
tify the presence of the mutations in the resulting bac-
terial colonies prior to culture. Growth of all DV2
clones in SURE
®2 cells was conducted in LB containing
50 μg/mL carbenicillin at 28 to 30°C for approximately
24 to 48 hours with shaking. DV2 plasmid DNA was
recovered using the Wizard
® Plus Minipreps DNA Puri-
fication System (Promega, Madison, WI) following man-
ufacturer’s instructions. All DV2 deletion mutant clones
were confirmed by sequence analysis (Eurofins MWG
Operon, Huntsville, AL).
In vitro transcription and RNA transfection
Transcripts were generated for each DV2 mutant clone
using the RiboMAX™ Large Scale RNA Product Sys-
tems for T7 RNA Polymerase (Promega) following man-
ufacturer’s instructions, with the addition of RNA cap
analog 7 mg(ppp)G (NEB # S1404S). The RNA tran-
scripts were transfected into Vero and C6/36 cells as
follows: Cells were pelleted and washed in RNase free
electroporation buffer (PBS-D for Vero and MOPS for
C6/36) and resuspended in their respective buffers at a
concentration of 1 × 10
7 to 5 × 10
7 cells/ml. RNA
transcripts were added to 400 μl of cells and electropo-
rated at 1.0 KV, 50 μF and 8 resistance using the BioRad
Gene Pulsar II (Bio-Rad Laboratories, Hercules, CA).
The transfected cells were then plated at different con-
centrations in three different 24 well plates with 1.0 ml
of the media and incubated at 37°C for Vero cells and
28°C for C6/36 cells for 1 hour with slow rocking. The
media was removed and the plates overlayed with 1.0
ml of 1% carboxymethylcellulose (CMC) in 1X Vero
media or 1X C6/36 media and incubated for 7, 10 and
14 days. The plates were developed by focus assay.
Focus assay
The focus assay may be developed as a colorimetric or
fluorescent assay using antibodies labeled with either
HRPO (color substrate) or Alexa Fluor fluorescent dye.
For the color assay, plates with transfected or infected
cells were washed twice with 1X PBS and fixed with
80% methanol for 15 minutes at room temperature, fol-
lowed by incubation with antibody dilution buffer (5%
skim milk in 1X PBS-D) for 10 minutes. Primary anti-
body (a-DV NS1 glycoprotein, Abcam #ab41623, Cam-
bridge, MA) was added at a dilution of 1:400 in
antibody (Ab) dilution buffer and incubated for 1 hour
at 37°C with slow rocking. The wells were then washed
twice with 1X PBS followed by the addition of second-
ary antibody conjugated with horse radish peroxidase
(HRP) (Sigma # 8924, St. Louis, MO) at a dilution of
1:500 in Ab dilution buffer. Wells were washed again
twice with 1X PBS. Foci were visualized by the addition
of 150 μl TrueBlue™ peroxidase substrate (KPL# 50-78-
02, Gaithersburg, MD) to each well and developed for
~15 minutes. Foci were counted and titer determined in
focus forming units/ml (ffu/ml) of virus. For the fluores-
cent assay, the protocol is similar to the color assay with
the following exceptions: Cells were fixed for 20 minutes
at room temperature in 100% methanol. A second 10
minute incubation with 1X PBS plus 0.05% Tween, fol-
lowed by 2 washes with 1X PBS plus 0.2% BSA. Anti-
body was diluted in 1X PBS + 0.2% BSA. The washes
between the primary and secondary antibodies were per-
formed in 1X PBS + 0.2% BSA. The secondary antibody,
Alexa fluor
® 488 F(ab’)2 fragment of goat anti-mouse
IgG (Invitrogen # A-11017, Carlsbad, CA), incubation
was conducted for 45 minutes in darkness. After the
final wash, 50 μl of water was added to each well for
visualization of the fluorescent foci.
Primary Virus Screen
A mutant virus screen was developed to determine the
infectivity of each mutant virus by visualizing and count-
ing foci of infection [14]. The screen was performed by
first transcribing the linearized mutant DV2 DNA clones
into RNA as described previously [11,15]. RNA transcripts
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The transfected cells were then plated out at different con-
centrations in three different 24 well plates with 1.0 ml of
the media and incubated at 37°C for Vero cells and 28°C
for C6/36 cells for 1 hr with slow rocking. The plates were
overlayed with 1.0 ml of 1% CMC in 1X Vero media or 1X
C6/36 media and incubated for 7, 10 and 14 days. Foci
were visualized by color focus assay and scored. Each
focus represents an infectious center demonstrating that
the virus is able to infect the neighboring cells and is con-
sidered a plus in this screen.
Secondary Screen
DV2 mutant clones that passed the first screen (i.e.
demonstrated the ability to produce foci of infection),
were transcribed into RNA and transfected again into
C6/36 cells. The transfected cells were then transferred
to 25 cm
2 flasks and incubated for 7 days at 28°C. The
virus was collected and amplified once by infecting
another flask of C6/36 cells. After amplification, virus
was harvested on day 7 and titrated using either Vero or
C6/36 as indicator cells. Serial viral dilutions were pre-
pared with dilution buffer (PBS-D + 3% FBS) and 200 μl
of virus. Each dilution was used to infect cell mono-
layers in 24 well plates for 1 hour at room temperature
or 37°C. The infected cell monolayers were then over-
layed with 1.0 ml of 1% CMC in 1X Vero media or 1X
C6/36 media and incubated at their respective tempera-
tures for 7 days. Foci of infection were detected by
focus assay as described above. Once a measurable titer
was observed for the mutant viruses, the virus was used
to infect Vero and C6/36 cell lines at an MOI (multipli-
city of infection) of ~0.03 ffu/cell. At day 7 post-infec-
tion, the virus was harvested and titrated as described
above in order to determine the host-range phenotype.
Mutants which exhibited the desired host-range pheno-
type were then amplified and plaque purified.
Infection and purification of selected mutants
The WT and DV2 mutants were grown in the Aedes
albopictus mosquito-derived C6/36 cell line. Cells were
split one day prior to infection at a ratio of 1:3. Subcon-
fluent monolayers of C6/36 cells were infected at an
MOI of ~0.03 ffu/cell. Virus was diluted in C6/36 media
and each 75 cm
3 flask infected with 1.0 ml of diluted
virus for 1 hour at room temperature. After the initial
infection, 4.0 ml of fresh media was added to each flask.
Flasks were then incubated for 7 days at 28°C. Virus
was harvested by centrifugation of the supernatant at
4000 rpm for 10 min. Purification and concentration of
WT and mutant DV2 were achieved using isopycnic
ultracentrifugation with iodixanol (Optiprep) gradients
(Sigma, St. Louis, MO). Virus was spun to equilibrium
in gradients of 12% to 35% iodixanol and isolated twice.
Expression and Processing of DV2 mutant proteins
Analysis of the production and processing of DV2 host-
range mutant proteins was done using PAGE and wes-
tern blots and were done on virus from A. albopictus
C6/36 cells. Mosquito cells were infected with WT,
DV2ΔGVII, and DV2ΔLIG and incubated at 28°C for 1
week. Infected mosquito cell supernatants were then
harvested and purified in iodixanol gradients as
described above. Purified virus amounts were deter-
mined using an EZ-Q protein determination kit (Invitro-
gen, Carlsbad, CA). Protein purity was then determined.
Twenty-five μl of each preparation was loaded onto 4-
12% bis-tris gradient gels (Invitrogen) and was stained
with colloidal Coomassie (Pierce, Rockford,IL) to deter-
mine purity. Proteins from a duplicate gel were trans-
ferred to a polyvinylidene difluoride membrane and
blotted as described previously [16] with the following
modifications: Primary anti-whole dengue virus mouse
monoclonal antibody (Abcam #ab9202) was used for
detection; an anti-mouse-HRP conjugate was used as a
secondary antibody; and viral proteins were visualized
by the addition of TrueBlue™ peroxidise substrate
(KPL, Gaithersburg, MD) to correctly assign the E and
M proteins within the virus particles.
Preparation of virus inoculum for mouse studies
Mosquito cells (C6/36) were infected with WT,
DV2ΔGVII, and DV2ΔLIG and mutants and incubated
at 28°C for 1 week as described above. Infected mos-
quito cell supernatants were then harvested and purified
twice in iodixanol gradients as described above. Infected
mosquito cell supernatants were then harvested and
concentrated by tangential flow filtration (TFF) using a
100 kDa cut off membrane as per manufacturer’s
recommendations (PALL, Post Washington, NY) and
further purified in iodixanol gradients as described
above. Twenty-five μl of each preparation was loaded
onto a 4-12% bis-tris gradient gel (Invitrogen) to test for
purity. Protein purity was determined using 4-12% bis-
tris gradient gels (Invitrogen) and stained with colloidal
Coomassie (Pierce, Rockford,IL) to determine purity.
The inoculum mass to inject per mouse was determined
from these assays. This investigation conformed to the
Guide for Care and Use of Laboratory Animals pub-
lished by NIH (No 82-23, rev 1996). The protocol was
approved by the Institutional Animal Care and Use
Committee at Immunobiosciences, Inc., our subcontrac-
tor for all animal studies.
RT-PCR analysis of mutant viruses
To confirm that the desired deletions remained intact in
virus grown in cell culture, RNA was extracted from
each mutant virus, reverse transcribed, and amplified by
PCR (RT-PCR). RNA extraction was performed by two
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from a minimum of 10
4 ffu of virus by pelleting the
virus at 50,000 rpm in a SW55Ti (Beckman Coulter,
Brea, CA) rotor for 1 hour. The pelleted virus was
extracted as described previously [15]. The RNA pellet
was resuspended in 10 μl of diethyl pyrocarbonate
(DEPC) treated water and checked on 1% agarose gel.
For smaller quantities of virus, a second method of puri-
fication was employed. Viral RNA was harvested from
C6/36 cells by RNeasy Mini kit (Qiagen, Valencia, CA).
Infected cells were scraped off flasks on Day 7 post-
infection and suspended in media at a cell density of ~
1×1 0
7 cells/ml. Cells were spun down, resuspended in
lysis buffer, and homogenized. Viral RNA was purified
as directed according to manufacturer’s instructions.
The resulting RNA was suspended in 30 μlo fR N a s e
free water and checked on a 1% agarose gel.
The extracted RNA was reverse transcribed and
amplified by PCR using the One-Step RT-PCR kit (Qia-
gen). Primers were designed for use in the RT-PCR
reaction by analysing the folded DV2 RNA structures to
optimize RNA binding accessibility [17]. The products
generated in the RT-PCR reaction (~ 640 bp) were phe-
nol/chloroform extracted, precipitated and sequenced to
confirm the identity and presence of deletions. Some of
the RT-PCR products were of insufficient quantity and
quality to be sequenced directly. These products were
amplified by nested PCR, subcloned into the pDrive
cloning vector and transformed in QIAGEN EZ Compe-
tent cells using the QIAGEN PCR cloning
plus kit (Qia-
gen). White colonies containing the vector-ligated PCR
product were amplified and the minipreped DNA was
sequenced for verification (Eurofins MWG Operon).
Focus reduction neutralization test (FRNT)
The relative amount of virus-neutralizing antibody pre-
sent in the mouse sera was determined by a focus
reduction assay on Vero cells, which is similar to the
standard Plaque Reduction Neutralization Test [1]. The
assay was performed as described above for the focus
assay, with the addition of a pre-incubation step to
allow serum antibody to bind WT DV2. In short, serum
samples were heat inactivated for 30 minutes at 56°C. A
dilution of 1:10 for each sample was prepared followed
by serial 2-fold dilutions in dilution buffer containing
3% FBS. Each dilution was mixed with an equal volume
of virus suspension containing 50 ffu of WT DV2 and
incubated at 37°C for 1 hour. 200 μl of the mixture was
then added to duplicate wells seeded with Vero in a 24
well plate. After 1 hour of adsorption at 37°C, the cells
were overlayed with 1X Vero media containing 1%
CMC. At day 7 post-infection, antibody titers were
determined by developing the plates according to the
focus assay protocol. Neutralizing antibody titers
(FRNT50) were reported as the highest dilution of the
sera that reduced focus formation by 50%.
Experimental design for determination of neutralizing
antibody titers
To evaluate DV2 specific neutralizing antibody
responses, five groups (n = 5) of 8 week old BALB/cJ
mice were inoculated subcutaneously (SC) with 29 μg
(~10
2-10
3 ffu/mouse) of purified WT DV2, DV2ΔLIG,
DV2ΔGVII, or iodixanol buffer alone. Protein estimates
were made using the EZQ
® Protein Quantitation Kit
(Molecular Probes). Mice were boosted with an equal
dose on Day 14 and serum samples were collected from
all groups on Day 28, at the termination of the study.
The relative amount of virus-neutralizing antibody pre-
sent in mouse sera was determined by focus reduction
neutralization test as described above (12).
Transmission Electron Microscopy
Vero or C6/36 cells were transfected with RNA tran-
scribed from WT DV2, DV2ΔLIG, or DV2ΔGVII clones.
Incubation proceeded at 37°C for 16-18 hours, after
which the cell monolayers were scraped from the flasks
a n dp e l l e t e db yl o ws p e e dc e n t r i f u g a t i o n .C e l lp e l l e t s
were washed twice with PBS and fixed with 3% glutaral-
dehyde (Ladd Research Industries, Inc., Williston, VT)
in 0.1M cacodylic acid buffer pH 7.4 (Ladd Research
Industries). After washing 3 times with 0.1M cacodylic
acid, cells were stained with 2% osmium tetroxide in
cacodylic buffer for 1 hour. Cells were then washed as
before and embedded in 2% agarose. Agarose containing
the cell sample was then pre-stained with 1% uranyl
acetate (Polaron Instruments Inc., Hatfield, PA) over-
n i g h ta t4 ° C .T h es a m p l e sw e r ew a s h e da n dc a r r i e d
through sequential dehydration with ethanol. Infiltration
was achieved using SPURR compound (LADD Research
Industries). Next blocks were trimmed on an LKB
NOVA Ultrotome (Leica Microsystems, Inc., Deerfield,
IL). Ultra-thin sections were obtained and stained with
5% uranyl acetate in distilled water for 60 minutes and
in Reynolds lead citrate pH 12 (Mallinkrodt Baker Inc.,
Paris, KY) for 4 minutes. The samples were examined at
80 kV in a JEOL JEM 100S transmission electron
microscope.
Results
Production of Dengue virus TMD mutants
The exact sequences or structures of Flavivirus TMDs
(including DV) E proteins are not precisely known, how-
ever they can be predicted with a high degree of cer-
tainty by sequence analysis [18]. The TMDs of
Flaviviruses are predicted to be shorter than those of
Alphaviruses, such as SV (DV14-16 amino acids com-
pared to SV 26-27 amino acids), based on the sequence
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endoplasmic reticulum (ER) [18,19]. This prediction is
supported by physiological differences in the virus
assembly. Unlike Alphaviruses that bud from a cell’s
plasma membrane, Flavivirus particle budding occurs
from the ER [20] which is thinner and contains less cho-
lesterol than the plasma membrane [10]. This observa-
tion is consistent with the putative shorter TMDs
predicted to occur in Flaviviruses. As is found for
Alphaviruses, Flavivirus TMDs have no consensus
sequence but model as hydrophobic helices [21]. Based
on these data, we predict that the shorter length of the
Flavivirus TMDs will require fewer deletions to produce
the desired host-range phenotype as observed in the
Alphavirus Sindbis. DV2 has two TMDs targeted for
deletion mutagenesis in this study: the first TMD of the
E protein (E-T1), predicted to contain 16 amino acids,
and the first TMD of the M protein (M-T1), calculated
to contain 14 amino acids [3]. Deletions of 1 to 5 amino
acids were created sequentially in each TMD, producing
mutants containing 11 to 15 amino acids (E-T1) or 13
to 9 amino acids (M -T1) remaining in the membrane.
Thirty-four DV2 E-T1 and 9 M-T1 deletion mutants
were produced in DV2 (Table 1). Transcripts produced
from each clone were transfected into cultured Aedes
albopictus C6/36 (insect) and Vero (mammal) cells as
described in Materials and Methods. Transfected cells
were transferred to 24 well plates and incubated for 7 to
10 days at 28°C or 37°C, respectively. At the end of the
incubation period, the presence of virus was visualized
by focus assay.
Analysis of the DV2 deletion mutants
The transmembrane domains of membrane proteins are
predicted to exist as a-helices within the membrane
bilayer [22]. This structure is preferentially adopted due
to the lack of water in the lipid bilayer resulting in greater
stability of the TMD side chains in a helical structure
[23]. This stability results from the ability of the carbonyl
oxygen of each residue to form hydrogen bonds with the
backbone HN of every fourth residue along the helical
vertical axis [24]. While the exact geometry of the helix
depends on the sequence there are basic physical proper-
ties of an ideal a-helix. There are 3.6 residues per helical
turn which is a rotation of 100 degrees/residue, or one
complete turn of 360 degrees. Thus, depending on the
size of the TMD the relative position of the amino and
carboxyl terminal ends will vary along the vertical helical
axis. For the purposes of this discussion the angles which
are referred to are the smallest angles either to the right
or left direction with reference to the amino acid at the
origin and the carboxyl terminus.
As a working model the sequence 452SWTMKILIG-
VIITWIG467 (16 amino acids) was chosen as the E1
transmembrane region to be targeted for mutagenesis
(Table 1). The sequence was determined based on pre-
vious studies, the present work and also on independent
hydrophobicity plot analyses [3,18,21,25]. In the 34
mutants constructed certain trends were observed. Dele-
tions were better tolerated when the viruses were grown
in Vero cells. Because the size of the deletion was not
directly related to the ability of the mutant to produce
virus from these cells (Δ1-5 amino acids), membrane
thickness did not appear to be a sole factor in produc-
tion of most of the mutants. Certain mutants did not
grow in either mammalian or insect cells (see table 1).
One deletion of five residues which did not produce
virus in either cell line was Δ457ILIGV461. Other five
amino acid deletions were tolerated in Vero cells sug-
gesting that five residues can be deleted; however, the
region 457ILIGV461 is critical for virus production from
both Vero and C6/36 cell lines. Because LIG and GVII
can be deleted and produce host-range mutants favour-
ing growth in insect cells the region LIGVII may be
important for interactions of the E TMD. A second
mutant, ΔK456,was not tolerated in either cell line sug-
gesting that this amino acid is important for virus pro-
duction in both cell lines or that this position in the
helix has specific structural requirements since other
single amino acid deletions did produce virus from both
hosts. The deletion of M455 also abrogated virus produc-
tion from both host cells. This residue is adjacent to
K456 which as a single deletion is also critical to expres-
sion in both host cells. When both residues are deleted
(ΔMK455-56)virus production was restored only in Vero
cells. Substitution of A for K456 restored virus produc-
tion suggesting that structural requirements were re-
established and that the amino acid K is not required at
this position. A third mutant which did not produce
virus in either cell line was ΔIIT462-64. This phenotype
could be due to a critical distortion in the geometry of
the ΔIIT462-64 TMD because ΔTa n dΔIT are able to
produce virus in Vero.
while Vero cells were generally more tolerant than the
C6/36 cells to disruptions in the E1 TMD there were
some differences seen in the C6/36 expressed TMD
deletion mutants. I463 is a required residue for virus pro-
duction in C6/36 cells. Since other single amino acid
deletions were tolerated in these cells, again this result
could be explained by the requirement for a specific
amino acid at this position or disruption of the neces-
sary helical geometry at this residue. Because a second
I462 is available to replace the I463 deletion it is possible
that the necessary geometry is affected in this mutant. It
is of interest that the deletion of I463 is included in the
ΔGVII which restores virus production in C6/36 cells. A
deletion of four amino acids would approximate a full
helical turn and restores the ability of ΔGVII to produce
Smith et al. Virology Journal 2011, 8:289
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Page 6 of 15virus lost by the deletion of I463. As would be expected
for a virus with such a wide host range, one mutant
ΔG460 displayed a phenotype which was also a host-
range mutant but was selective for Vero cells. Notably,
no two or five amino acid deletion mutants produced
virus in C6/36 cells. This was not the case for double
deletion mutants grown in Vero cells possibly due to
the greater flexibility of the mammalian membrane and
the immediate lipid environment. For the mosquito cells
a two amino acid deletion is the most disruptive dele-
tion to the orientation of the NH terminus with respect
to the COOH terminus placing the backbone of the ter-
mini 140 degrees from one another normal to the cen-
tral helical axis. The predicted geometry for this wild
Table 1 Dengue virus deletion mutants in the first TMD of the E protein of DV2
SEQUENCE E-T1 Domain Foci Critical AA Vero Critical AA C6/36
Vero C6/36
WT DV2 452SWTMKILIGVIITWIG467 ++ ++
1 ΔIG466-67 SWTMKILIGVIITW– - - 2aa
2 ΔW465 SWTMKILIGVIIT-IG +-
3 ΔT464 SWTMKILIGVII-WIG +- T464
4T 464A SWTMKILIGVIIAWIG + +
5 ΔIT463-64 SWTMKILIGVI–WIG +- 2aa
6 ΔIIT462-64 SWTMKILIGV—WIG - - T464
7 ΔVIIT461-64 SWTMKILIG——WIG +- T464
8 ΔGVIIT461-64 SWTMKILI———WIG +- 5aa 5aa
9 ΔI463 SWTMKILIGVI-TWIG +- I463
10 ΔII462-63 SWTMKILIGV–TWIG +- 2aa
11 ΔVII461-63 SWTMKILIG—TWIG - -
12 ΔGVII460-63 SWTMKILI——TWIG + +
13 ΔIGVI459-64 SWTMKIL——ITWIG +-
14 ΔIGVII459-63 SWTMKIL———TWIG +- 5aa 5aa
15 ΔV461 SWTMKILIG-IITWIG + +
16 ΔGV460-61 SWTMKILI–IITWIG +- 2aa
17 ΔIGV459-61 SWTMKIL—IITWIG + +
18 ΔLIGV458-61 SWTMKI——IITWIG +-
19 ΔILIGV457-61 SWTMK———IITWIG - - 5aa 5aa
20 ΔG460 SWTMKILI-VIITWIG + +
21 ΔIG459-60 SWTMKIL–VIITWIG +- 2aa
22 ΔLIG458-60 SWTMKI—VIITWIG + +
23 ΔILIG457-60 SWTMK——VIITWIG + +
24 ΔILI457-59 SWTMK—GVIITWIG + +
25 ΔIL457-58 SWTMK–IGVIITWIG - - 2aa
26 ΔI457 SWTMK-LIGVIITWIG +- I457
27 ΔKI456 SWTM–LIGVIITWIG +- 2aa
28 ΔK456 SWTM-ILIGVIITWIG - - K456 K456
29 K456A SWTMAILIGVIITWIG + +
30 ΔMK455-56 SWT–ILIGVIITWIG +- 2aa
31 ΔM455 SWT-KILIGVIITWIG - - M455 M455
32 ΔTM454-55 SW–KILIGVIITWIG + - 2aa
33 ΔT454 SW-MKILIGVIITWIG + +
34 ΔW453 S-TMKILIGVIITWIG + +
Deletions in the E-T1 domain of DV2 were produced by site-directed PCR-based mutagenesis. The mutant viruses were screened by a DV2 mutant transfection
by focus assay performed on 24-well plates in both mammal (Vero) and insect (A. Albopictus, C6/36) cells. Foci were visualized immuno-histochemically. Mutant
viruses able to produce foci of infection were scored as positive (+) or negative (-) after 10 days of infection. Virus mutants giving foci in both hosts were
amplified and titered to determine phenotype. AA; amino acid.
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the location of the NH and COOH termini within 60
degrees from the origin of the helix (the NH terminus
located on the luminal side of the membrane). Thus, in
E mutants’ where the helical geometry contains a double
deletion, a 140° angle of entry to exit from the mem-
brane of these mutants did not produce virus in C6/36
cells. Also, there are no mutants that delete I457,o rT 464
capable of growth in insect cells making these essential
residues or locations. It is of note that while W465 is
completely conserved among DV2, its’ deletion was tol-
erated in Vero cells. Motifs such as these may be host
adaptive sites required for function in one specific host
but not the other. Taken together these data identify the
region or sequence 458LIGVII463 as the region of the
TMD which can be mutated to produce host-range
mutants.
The collection of mutants made in the DV2 M protein
is shown in Table 2. The TMDs of both glycoproteins
were targeted for mutagenesis because one host-range
mutant in Sindbis virus E1 was identified (Ribeiro, M et.
al. in preparation). While the M and E domains cannot
be directly compared because of the difference in size
(15 amino acids compared to 16 in the E1 model) gen-
eral observations can be made. With the exception of
mutants 7 and 8 (Table 2), production of mutant virus
was seen from both cell lines. However, no host-range
mutations were identified in the T-1 region of M.
Thus, two host range deletion mutants predicted by
the original hypothesis were identified in the E1 TMD
and were selected for further analysis. While the initial
hypothesis was that host-range phenotypes would be
found among the larger mutants which could only prop-
erly assemble in the thinner insect membranes, it is
clear from these results that the expression of a host-
range phenotype is not only a function of the size of the
deletion, but also of the helical geometry within the
membrane, the membrane composition and by exten-
sion its effects outside the membrane. This methodology
will be extended to look for equivalent host-range
mutants within the corresponding regions of other sero-
types of Dengue 1, 3 and 4 which may follow a similar
pattern of expression. The importance of the E1 TMD
deletion structures reported herein will be further dis-
cussed in terms of two desired phenotypes. The deletion
mutants screened and selected for further study were
determined by their ability to 1) produce host-range
mutants with preferential growth to the insect host and
2) induce a neutralizing antibody immune response in a
mouse model.
DV2 mutants with deletions in the TMD of E or M
proteins make normal viral protein and infectious virus
We have identified a region of the DV2 E-T1 domain
which when removed yields a host-range phenotype in
which virus production/infectivity is shifted to favor
production in insect vs. mammalian cells. To date, 43
independent mutations have successfully been pro-
duced in the full-length DV2 clone (Tables 1 and 2).
All DV2 E-T1 and M-T1 deletion mutant clones were
confirmed by sequence analysis (Eurofins, MWG
Operon).
A preliminary DV2 mutant screen was used to deter-
mine which DV2 mutant clones were able to produce
infectious centers (foci). This screen is a direct plating
of C6/36 and Vero cells transfected with transcripts of
each mutant virus. These results did not reveal the
host-range phenotype because titers were not calculated;
instead the mutants were scored positive or negative
depending on the presence or absence of foci. These
results determined which mutants continued to the next
screen (phenotypic analysis).
Table 2 Dengue virus deletion mutations produced in the first TMD of the M protein of DV2
SEQUENCE M-T1 DOMAIN Foci Critical AA Vero Critical AA C6/36
Vero C6/36
WT DV2 245PGFTMMAAILAYTIG259 ++ ++
1 ΔA251 PGFTMM-AILAYTIG + +
2 ΔAA251-52 PGFTMM–ILAYTIG - - AA251-52 AA251-52
3 ΔAAI251-53 PGFTMM—LAYTIG - - AAI251-53 AAI251-53
4 ΔAAIL251-54 PGFTMM——AYTIG + +
5 ΔAAILA251-55 PGFTMM———YTIG - - 5aa 5aa
6 ΔM250 PGFTM-AAILAYTIG + +
7 ΔMM249-50 PGFT–AAILAYTIG +- M 249
8 ΔTMM248-50 PGF—AAILAYTIG +- M 249
9 ΔFTMM247-50 PG——AAILAYTIG - - 5aa 5aa
The primary DV2 mutant focus assay screen determined which mutants were able to produce foci of infections in Vero and A. Albopictus C6/36 cells. (+) indicates
the presence of foci and (-) indicates no foci were observed. AA; amino acid.
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importance of the E-T1 and M-T1 domains in the
assembly and expression of DV2. The focus assay
enabled the visualization of infectious centers in the
cells infected by the viral RNA. Based on number and
size of foci, every mutant, even the single amino acid
deletions, had reduced expression in both Vero and C6/
36 cells. Twelve DV2 deletion mutants [9 in E-T1:
DV2ΔG460, ΔV461, ΔW453, ΔT454, ΔLIG, ΔGVII, Δ ILIG,
ΔILI and ΔIGV (Table 1) and 3 in M-T1: DV2ΔA,
ΔAAIL, and ΔM250 (Table 2)] capable of producing foci
of infection in both C6/36 and Vero cells were identi-
fied. Five mutants expressing the best titers (E-T1
mutants DV2ΔG, DV2ΔLIG, ΔIGV, and ΔGVII; M-T1
mutant DV2ΔAAIL) were selected to proceed to the
secondary screen.
Deletion mutants constructed around a specific TMD
position/region exhibit host-range phenotype
Five mutant viruses from the primary screen underwent
a second round of screening to ascertain phenotype.
The mutants were transcribed into RNA and transfected
into the preferred host, C6/36 cells. The mutant viruses
were then grown in both Vero and C6/36 (at the same
starting MOI of ~0.03 ffu/cell) to determine growth
characteristics in mammalian vs. insect cells. Virus was
harvested on day 7 and titered on Vero cells. The foci
formed by these mutants were very small and were
visualized using a more sensitive fluorescent focus assay
(described in Methods). Mutant viruses with preferential
growth in the C6/36 mosquito cell line and attenuated
growth in Vero cells as defined by at least 2 orders of
magnitude less virus production in Vero were consid-
ered to express the host-range phenotype.
Out of 5 mutants that produced foci in both C6/36
and Vero cells and were chosen to proceed to the sec-
ondary screen, only 2, DV2ΔLIG and DV2ΔGVII,
showed the host-range phenotype restricted to preferen-
tial growth in the insect cells (Figure 2). DV2ΔIGV grew
equally well in both cell lines (Figure 2). The opposite
host-range phenotype, favoring growth in mammalian
cells was observed for the DV2ΔGm u t a n t( F i g u r e2 ) .
Upon further passage, the M-T1 domain mutant
DV2ΔAAIL did not yield measurable titers in either
Vero or C6/36 cells (data not shown).
WT DV2 routinely generates titers of 10
6 ffu/ml in
Vero cells and 10
7 ffu/ml in C6/36 cells. It was observed
that most mutants gave lower titers as compared to WT
DV2, except DV2ΔIGV, which was quantitatively identi-
cal to WT in Vero cells, but was qualitatively (i.e. foci
were much smaller) reduced as compared to WT, as was
observed for DV2ΔLIG and DV2ΔGVII as well. Titers
were in the range of 10
3-1 0
4 ffu/ml for both DV2ΔGVII
and DV2ΔLIG mutants grown in C6/36 cells (Figure 2).
Protein expression and processing of DV2 host-range
mutants
The two DV2 host-range mutants DV2ΔGVII and
DV2ΔLIG were found to produce infectious virus, as
o b s e r v e di nt h ef o c u sa s s a y( T a b l e1a n dF i g u r e2 ) .I n
order to determine if all viral proteins were indeed pro-
duced and processed as in WT DV2, a western blot ana-
lysis was performed (Figure 3). Virus grown in mosquito
cells was harvested from the cell supernatant at day 7
post-infection and examined by SDS-PAGE. Equal pro-
tein amounts from each virus were added to the gel. To
confirm the presence of specific DV proteins, the gel
was transferred to substrate and blotted with an anti-
DV whole virus antibody. Visualization of the protein
bands revealed a similar banding pattern to that of WT
DV2 (Figure 3) showing preM and E, verifying the cor-
rect production and processing of virus proteins by the
mutants.
Electron micrographs of the mutants (DV2ΔGVII and
DV2ΔLIG) suggest impaired assembly
In order to analyse the differences in virus ultrastructure
between mammal and mosquito cells, thin sections of
cells infected with WT and mutant viruses were pre-
pared and evaluated. C6/36 (Figure 4A) and Vero (Fig-
ure 4B) cells were infected with the WT DV2. Virus
particles were observed in large paracrystalline struc-
tures within the mosquito cell (4A-arrows) and asso-
ciated with the mammalian plasma cell membrane (4B-
arrows). In Figure 4C, mosquito cells infected with the
DV2ΔGVII mutant exhibited similar amounts of virus
Figure 2 Host-range phenotype of DV2 mutants. Titers for the
WT DV2 and mutant viruses are shown. All virus strains were
grown in Vero (mammal; black bars) and the C6/36 (insect; gray
bars) cells to measure host-range phenotype. The titers of the
mutant viruses were determined by a fluorescent focus assay. Titers
of WT virus were measured by a colorimetric focus assay. DV2ΔIGV
did not display the host range phenotype and DV2ΔG was a host
range mutant which grew better in the Vero cells. Only DVΔGVII
and DVΔLIG were chosen for further analysis.
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Page 9 of 15production as compared to WT (arrows). However, in
mammalian cells infected with DV2ΔGVII (Figure 4D)
only the presence of nucleocapsids in the cytoplasm
could be detected in the thin sections (arrowheads) sug-
gesting a defect in assembly, budding and release of
virus into the supernatant. Cells infected with the
mutant DV2ΔLIG displayed a similar phenotype. The
presence of virus particles was observed in the cyto-
plasm of mosquito cells (Figure 4E-arrowheads) while
only nucleocapsids were detected in the cytoplasm of
mammalian cells (Figure 4F-arrowheads) [26]. These
phenotypes of WT, ΔGVII and ΔLIG were detected in
90%, 70% and 25% of observed cells respectively. These
observations clearly demonstrate differences in virus
production between cell types as expected for host-
range mutants. The specific defect in the assembly path-
way of these mutants in Vero cells is not known. It is
hypothesized that one aspect of the disrupted assembly
would be the inability of the E-T1 domain to integrate
properly into the membrane of the thicker mammalian
ER producing a host-range mutant as was seen in the
distantly related Alphavirus Sindbis [11]. While much
progress has been made in solving the molecular
mechanism of flavivirus assembly, it has yet to be estab-
lished how the mature particles are formed [27,28].
However these results clearly demonstrate differences in
virus assembly between the cell types as expected for
host-range mutants.
Mutants with host-range phenotypes generate
neutralizing antibody response in BALB/cJ mice
The goal of the subsequent mouse trial with the DV2
host-range mutants was to determine the in vivo immu-
nogenicity of each mutant. Previous research has con-
cluded that the murine model (BALB/cJ) is not
amenable for DV2 pathogenesis [29-32] but is useful for
the determination of antibody responses to dengue vac-
cine candidates [3,33-36]. The rationale for this study
was to determine if any antibody response could be
detected in an animal model other than non-human pri-
mates. Mutants possessing an insect cell preferential
host-range phenotype were analyzed for the ability to
generate neutralizing antibodies in BALB/cJ mice. The
subcutaneous route of infection was employed in order
to approximate a physiologically relevant DV transmis-
sion by mosquitoes. Gradient purified host-range
mutant virus was used as an inoculum. 29 μg of protein
in 100 μl of iodixanol in PBS-D, equivalent to ~10
2 to
10
3 total ffu was injected for each vaccine candidate
and WT DV2 control. As a negative control, iodixanol
buffer alone was injected into one mouse group. Each
inoculum was quantified using the EZQ
® Protein Quan-
titation Kit. The amount (29 μg) was chosen based on
the yield of the lowest titered virus (DV2ΔLIG) to
ensure all mice received equal doses. For wild-type virus
this was accomplished by using a low titer DV2 stock.
Both mutants were able to generate reciprocal antibody
titers at 50% virus neutralization (ND50)i nt h er a n g eo f
10-80 ND50. Mice inoculated with DV2ΔGVII produced
a higher neutralizing antibody response (80 and 40
ND50)a sc o m p a r e dt ot h o s ew h or e c e i v e dD V 2 ΔLIG
which gave a response of 20 and 10 ND50 or WT DV2
at 10 ND50. Four out of 5 mice in the DV2ΔGVII
group gave an ND50 between the range of 20-80 while
only 2 mice were responders in the DV2ΔLIG group,
with an ND50 of ~20 (Figure 5). Mice injected with buf-
fer alone exhibited no neutralizing antibody response.
RT-PCR analysis of amplified murine serum samples
taken at the conclusion of this study yielded no detect-
able virus indicating that the virus inoculum and any
subsequent replicating virus was cleared. Further studies
on the immunogenicity of these mutants and their uti-
lity as vaccine candidates will be conducted in non-
human primates.
Figure 3 Western blot analysis of DV2 host-range mutants.A4 -
12% bis-tris gradient gel was loaded with 5 μl of iodixanol-gradient
purified WT or 25 μl of mutant DV2 virus purified from the
supernatant of infected mosquito C7-10 cells. Proteins were stained
using a polyclonal serum raised against whole DV2. The size of the
molecular weight markers is indicated on the right in kDa. Lane 1,
WT DV2; Lane 2, DV2ΔGVII; Lane 3, DV2ΔLIG. E; E protein; preM,
preM protein.
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Page 10 of 15Figure 4 Electron micrograph thin sections of WT DV2, DV2ΔGVII, DV2ΔLIG viruses in the C6/36 line of mosquito cells (column 1;
frames A, C, & E) and the mammalian Vero cell line (column 2; frames B, D, & F). WT DV2 virus particles are seen in large
paracrystalline structures in infected mosquito cells (Figure 4A-arrows and inset). In infected mammalian cells, WT virus particles are
associated with the plasma cell membrane (Figure 4B-arrows, inset). Mosquito C6/36 cells infected with the DV2ΔGVII mutant display similar
amounts of virus particles (Figure 4C-arrows, inset) as compared to that observed in the WT virus infected mosquito cells. However, in
mammalian cells infected with DV2ΔGVII (Figure 4D) only the presence of nucleocapsids in the cytoplasm and associated with internal
membranes were detected in the thin sections (arrowheads and magnified in the inset). Similarly, DV2ΔLIG virus particles were observed in the
cytoplasm of infected C6/36 mosquito cells although fewer particles were observed (Figure 4E-arrowheads) while only nucleocapsids were
detected in the cytoplasm of the infected mammalian cells (Figure 4F-arrowheads, inset). Bars are 500 mM and the insets are 2X magnified from
the original.
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not revert to wild type virus
The host-range mutant viruses identified in this study
propagate two orders of magnitude less virus than the
WT virus in insect cells. These host-range mutants,
however, still produce two to three orders of magnitude
less infectious virus from Vero cells as compared to C6/
36. As a result, there may be some selective pressure on
the mutant viruses to revert to the WT virus in the
insect system. To confirm whether or not this was the
case, reversion of the mutant viruses to WT in the C6/
36 cells was evaluated over five serial passages. The cell
culture supernatant was collected from the infection
after each round of infection and the sequence of viral
RNA was analysed by RT-PCR. The mutant viruses
retained their deletions after 5 sequential passages in
C6/36 cells and no reversion to the WT DV2 sequence
was found. The same results were obtained when the
experiment was performed in mammalian Vero cells.
After 4 serial passages in the Vero cells, no WT virus or
reversions were recovered from the mutant virus
infected cells.
Discussion
In nature, arboviruses cycle between vertebrate and
invertebrate hosts in a complex life cycle. Vertebrate
and invertebrate membranes express divergent
biochemical and biophysical membranes of distinct phy-
siology. This difference has imposed on the arbovirus
genome the necessity to adapt to a vast divergence dur-
ing its life cycle. Taxonomically the Class Insecta is
defined as a group of cholesterol auxotrophs [37]. This
characteristic is an important distinction because choles-
terol alters the properties of membranes making them
thicker, more viscose and ion impermeable. A hypoth-
esis was previously put forth which predicted that alpha-
virus host-range mutants with preferential growth in the
invertebrate host could be constructed by producing
deletions in the TMD of the virus glycoprotein(s). This
theory was first tested and supported in the alphavirus
Sindbis (SV) [11]. It was further postulated that this
property of differential glycoprotein requirements for
TMDs anchored in the thinner and biochemically dis-
tinct insect membranes would apply to all arboviruses.
While two host-range mutants of DV2 were character-
ized in this study, analysis of a series of deletions in the
E-T1 and M-T1 domains of DV2 revealed a more com-
plex relationship between the transmembrane domain
and lipid bilayer. Other factors such as helical confor-
mation and interactions of specific amino acid residues
play a critical role in TMD function in each host.
Two significant contributions of this study to the field
of arbovirology are reported. First, data are presented
which identifies a region in the T1 domain of DV2 E, in
the sequence aa 458LIGVII463 which is essential for virus
assembly and infectivity in mammalian cells, but is not
required in insect cells, as predicted from the SV model
system. The membrane of the host cell is one critical
structural common denominator which the alpha and
flaviviruses have in these studies. It is of interest that
only the E protein produced host-range mutants while
M did not. It may be concluded from these observations
that M does not contain a TMD motif which can define
host-range but that it is of major importance in the for-
mation of infectious virions. While the E protein did
display a region which could be deleted to produce
host-range mutants restricted to growth in the insect
hosts, this observation suggests that M and E have
unique roles in virus assembly.
Second, both DV host-range mutations identified pro-
duced significant numbers of non-infectious virions in
the mosquito system. This was determined by measur-
ing the particle to pfu ratios of all these strains. WT
DV2 has a particle to pfu ratio of 10
3 particle/pfu while
ΔGVII and ΔLIG have particle to pfu ratios in the 10
6-7
particles/pfu range. This feature was a phenotype also
associated with the SV deletion mutants. The presence
of non-infectious particles in the vaccine strains could
present different epitopes or act as adjuvant. A signifi-
cant difference in the assembly of alpha and flaviviruses
is the association of the glycoprotein-modified viral
Figure 5 Murine neutralizing antibody titers were measured by
the focus reduction neutralization assay (FRNT) for mice
injected with WT DV2, the mutants DV2ΔLIG and DV2ΔGVII,
and iodixanol in PBS-D (mock). All assays were performed on
Vero cells. Individual mouse serum from each of the five mice in
each experimental group was analysed and the titers shown as the
reciprocal neutralization titer at 50% neutralization. Each bar
represents one mouse. Mice were injected with 29 μg of each virus,
equivalent to 2 × 10
2 ffu WT DV2, 4 × 10
2 ffu DV2ΔGVII, or 2.4 × 10
3
ffu DV2ΔLIG. Mice injected with the mock inoculum produced no
measurable neutralizing antibody.
Smith et al. Virology Journal 2011, 8:289
http://www.virologyj.com/content/8/1/289
Page 12 of 15membrane with the nucleocapsid. Alphaviruses are char-
acterized by the strong association of the E2 tail with
the nucleocapsid which is required for assembly and
infectivity [38]. The flaviviruses do not directly interact
with the nucleocapsid and the mechanism by which
virus budding occurs in association with the core is not
well understood [39,40]. Additionally, flaviviruses pro-
duce empty particles [40-42] which increase toward late
stages of infection (M. Ribiero, R. Hernandez personal
observation) suggesting that some component (viral or
host) is depleted as the infection progresses. These spe-
cific differences in the details of virus assembly in the
alpha and flavivirus systems underscore the importance
of the membrane in the host-range phenotype. It is for
this reason that it is expected that this technology for
the development of arbovirus vaccines can be applied to
other flaviviruses and alphaviruses.
The ability of DV to assemble host-range mutants in
insect cells was employed to test for DV vaccine strains
in mice. Although mice are not a model host for Den-
gue virus, this experiment was performed as a test of
the immunogenicity of selected host-range mutants
prior to study in a non-human primate model. Indeed,
the host-range mutants [43,44] were found to illicit high
neutralizing Ab compared to the wild-type control when
tested in BALB/cJ mice. DV2ΔGVII was found to elicit
a stronger neutralizing response in 4 out of 5 mice
tested while the DV2ΔLIG mutant showed a response in
2 of 5 mice injected. This differential response between
the mutants and WT, as well as between the 2 mutants
themselves, was not an unexpected result; this phenom-
enon was also observed in the SV system (5). These
results indicate that although E is truncated in the TM
domain, the E antigen is still presented to the host
immune system in an immunogenically competent con-
formation exceeding that seen in the wild-type infection.
Altering the length and composition of the E-T1 a-helix
may lead to changes in the conformation of that helix
that are transduced to the extracellular domain of the E
protein. Therefore, while all extracellular epitopes of the
host-range mutants are WT in sequence, they may have
an altered conformation that allows for better access to
existing or hidden neutralizing antibody epitopes, lead-
ing to a more robust and varied NAb response as com-
pared to WT. It will be of interest to determine if this
enhanced neutralizing effect is the result of a combina-
tion of altered immunogenic factors presented by these
mutants which engages the immune system in an alter-
nate pathway than other previously tested live attenu-
ated vaccine strains. More detailed studies of the
immunogenicity of these mutants are on-going. Of note
is that DV2ΔGVII, which is the larger of the two dele-
tion mutants (i.e. the E-T1 domain has fewer amino
acids) elicited six fold more neutralizing activity than
the smaller DV2ΔLIG deletion mutant. Although mice
are not normal hosts for DV, this study was done solely
to test the ability of these mutants to induce an immune
response in mice prior to further study. Other facets of
the immune response to these mutants will be evaluated
in a more suitable primate model. Although non-human
primates are also insufficient to predict vaccine safety,
immunogenicity and efficacy [43,45,46] monkey studies
will determine if these mutants meet the criterion to be
tested in humans [47,48].
It is expected that these types of mutations can be
constructed for DV1-4 and used to formulate a tetrava-
lent vaccine. This study describes a novel approach to
DV vaccine development in which only molecular biol-
ogy methods are required for production of a vaccine
strain. This combination of host-range mutants for
D V 1 - 4w o u l dc o n s t i t u t eal i v ev i r u sv a c c i n eg r o w ni n
insect cells. The DV host-range mutants were shown
not to revert to WT after multiple passages, displaying
genetic stability in the host used for production. The
mechanism of genetic stability of these host-range
mutants in insect cells is not known, but alphavirus
complementation does not occur in insect cells implying
component sequestration [5,49]. Further, although these
viruses exist as quasi-species due to the high error rate
of RNA polymerase; this did not affect the stability of
the deletion over five passages in vitro. These data pro-
vide further evidence that sequence elements which
define host-range are expressed in the arbovirus glyco-
protein TMDs and probably throughout the arbovirus
genome. This methodology will continue to be applied
to other pathogenic flavi and alphaviruses to produce
vaccine strains.
Conclusions
Deletions in the E-T1 TMD of DV2 were created that
produced an altered host-range phenotype favoring
growth in insect hosts. Factors other than TMD length
alone were also found to influence the phenotype of DV2
mutants. The E domain sequence 458LIGVII463 contains
motifs responsible for host specificity. Targeting arboviral
TMDs to create host-range mutants is a novel method of
producing potential live vaccine candidates and may be
applied to many insect-transmitted viruses.
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